Once-weekly basal insulin is an option for selected adults with type 2 diabetes. Awiqli and Onswik are different products with different concentrations and transition schedules.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
Once-weekly basal insulin is an option for selected adults with type 2 diabetes. Awiqli and Onswik are different products with different concentrations and transition schedules. A supervised switch is essential.
Basal insulin provides background insulin action. Once-weekly products remain active for a long time, so dosing errors and low glucose can have prolonged effects. They do not automatically replace mealtime insulin.
The current US labels are for adult type 2 diabetes. Onswik is not recommended for type 1 diabetes because of severe low-glucose risk. Weekly treatment requires reliable monitoring and an ability to follow a product-specific weekly schedule.
Review current basal and mealtime insulin, glucose patterns, kidney function, and low-glucose history. Confirm access before changing treatment. The prescriber sets the initial and later doses, timing, and monitoring plan. Teach the exact pen and a written weekly record. Never calculate a conversion by multiplying the daily dose by seven yourself.
Bring insulin labels and devices, the exact daily regimen, meter or CGM report, kidney tests, and a record of lows. Describe work shifts, illness, or missed doses.
Do not use a concentrated pen as though it were another insulin. Never withdraw insulin from the pen into a syringe. Severe low glucose, accidental extra doses, or acute illness needs urgent advice. Keep existing insulin while awaiting a supervised switch.
Monitor more closely during a transition or dose change. Report lows promptly and keep a clear dose record. If the day or dose is uncertain, contact the clinician before another injection. A weekly schedule does not eliminate regular diabetes review.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
The current US Awiqli and Onswik indications are for adults with type 2 diabetes. Onswik is specifically not recommended for type 1 diabetes because of increased severe hypoglycemia risk. Do not replace a type 1 regimen with weekly insulin without specialist care.
No. Weekly insulin is basal or background treatment. Some people still need mealtime insulin or other diabetes medicines. The clinician reviews the whole regimen and glucose pattern before changing any part.
No. Initial switch doses, later weekly doses, timing, and monitoring differ by product and prior regimen. Multiplying the daily dose by seven yourself can cause dangerous low or high glucose. The prescriber must write the exact transition plan.
Do not repeat an injection when you cannot confirm whether it was taken. Check the written dose record and contact the clinician for product-specific advice. Monitor glucose as directed. An accidental extra dose can cause prolonged serious low glucose.
A weekly basal insulin may be self-injected after appropriate training when the prescription and care arrangement allow it. Confirm who teaches the exact pen and reviews glucose. Weekly dosing does not mean that no follow-up is needed.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
